Document is current
Any future updates will be listed below
-
Authors
Jabbour, Elias J. https://orcid.org/0000-0003-4465-6119
Kantarjian, Hagop M. https://orcid.org/0000-0002-1908-3307
Goekbuget, Nicola
Shah, Bijal D.
Chiaretti, Sabina
Park, Jae H. https://orcid.org/0000-0002-2903-5130
Rijneveld, Anita W.
Gore, Lia
Fleming, Shaun
Logan, Aaron C.
Ribera, Josep M. https://orcid.org/0000-0003-1042-6024
Menne, Tobias F.
Mezzi, Khalid
Zaman, Faraz
Velasco, Kelly
Boissel, Nicolas https://orcid.org/0000-0003-2091-7927
-
Funding
Funding for this research was provided by:
Amgen (No grant, No grant, No grant, No grant, No grant, No grant, No grant, No grant, No grant, No grant, No grant, No grant, No grant, No grant, No grant)
- License Information
-
More Information
Article History
Received: 19 September 2024
Revised: 18 October 2024
Accepted: 22 October 2024
First Online: 19 November 2024
Competing interests
: EJJ has received research grants from Pfizer, Takeda, Amgen, AbbVie, Novartis, Astex, Adaptive Biotechnologies, and Ascentage and served as a consultant and on advisory boards for Pfizer, Takeda, Amgen, AbbVie, BMS, Novartis, Genentech, Adaptive Biotechnologies, and Ascentage. HMK has received/served as honoraria/advisory board/consulting for AbbVie, Amgen, Amphista, Ascentage, Astellas, Biologix, Curis, Ipsen Biopharmaceuticals, KAHR Medical, Labcorp, Novartis, Pfizer, Shenzhen Target Rx, Stemline, and Takeda and has received research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, and Novartis. NG has received institutional research funding from Amgen, Clinigen, Incyte, Jazz, Novartis, Pfizer, and Servier and received speaker honoraria or fees for advisory board participation from Amgen, AstraZeneca, Autolus, Celgene, Clinigen, Gilead, Incyte Jazz, Novartis, Pfizer, and Servier. BDS has served as a consultant and an educational advisor for Deciphera, Takeda, Kite, Novartis, Beigene, Pfizer, Jazz, BMS, Amgen, Adaptive, Lilly, Autolus, Syndax, Precision Biosciences, and Astra Zeneca; has received grants and served as an investigator for initiated trials for Kite, Jazz, and Servier; and has served on a data safety monitoring committee for Pepromene Bio. SC has served as a consultant and on advisory boards for Amgen, Incyte, Gilead, and AbbVie. JHP has received consulting fees from Affyimmune Therapeutics, Amgen, Autolus, Be Biopharma, Beigene, Bright Pharmaceutical Services, Caribou Biosciences, Curocell, Galapagos, In8Bio, Kite, Medpace, Minerva Biotechnologies, Pfizer, Servier, Sobi, and Takeda; received honoraria from OncLive, Physician Education Resource, and MJH Life Sciences; served on scientific advisory boards of Allogene Therapeutics, Artiva Biotherapeutics and Green Cross Biopharma; and received institutional research funding from Autolus, Genentech, Fate Therapeutics, InCyte, Servier, and Takeda. AWR has no competing interest. LG is an unpaid advisor to Amgen on the development of oncology products in pediatric patients. SF has served as an advisory board member for Amgen, Astellas, Gilead/Kite, Jazz, Pfizer, and Jazz; received speakers’ honoraria from Amgen, BMS, Gilead/Kite, Jazz, Pfizer, and Novartis; and received research funding from Amgen. ACL has received consulting honoraria from Amgen, AbbVie, Actinium, Sanofi, and Takeda, and research funding from Amgen, Autolus, Incyte, Kadmon/Sanofi, Kite/Gilead, Pharmacyclics, and Talaris. JMR has served as a speaker for and received advisory board honoraria from Pfizer, Amgen, Shire, and Ariad; has received research support from and participated in clinical trials with Amgen; and has participated in clinical trials with Pfizer and Ariad. TFM has served on the advisory board for Amgen, Incyte, Gilead, Novartis, and Pfizer. KM, FZ, and KV are employees of and shareholders in Amgen. NB has received personal/consulting fees from Amgen, Gilead Sciences, Novartis, Servier, and Pfizer.
